7jji
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Structure of SARS-CoV-2 3Q-2P full-length prefusion spike trimer (C3 symmetry)== | ==Structure of SARS-CoV-2 3Q-2P full-length prefusion spike trimer (C3 symmetry)== | ||
| - | <StructureSection load='7jji' size='340' side='right'caption='[[7jji]]' scene=''> | + | <StructureSection load='7jji' size='340' side='right'caption='[[7jji]], [[Resolution|resolution]] 3.60Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7JJI OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=7JJI FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[7jji]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/2019-ncov 2019-ncov]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7JJI OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=7JJI FirstGlance]. <br> |
| - | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=7jji FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7jji OCA], [http://pdbe.org/7jji PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=7jji RCSB], [http://www.ebi.ac.uk/pdbsum/7jji PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=7jji ProSAT]</span></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EIC:LINOLEIC+ACID'>EIC</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=VCG:2-hydroxyethyl+2-deoxy-3,5-bis-O-(2-hydroxyethyl)-6-O-(2-{[(9E)-octadec-9-enoyl]oxy}ethyl)-alpha-L-xylo-hexofuranoside'>VCG</scene></td></tr> |
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">S, 2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=2697049 2019-nCoV])</td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=7jji FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7jji OCA], [http://pdbe.org/7jji PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=7jji RCSB], [http://www.ebi.ac.uk/pdbsum/7jji PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=7jji ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/SPIKE_SARS2 SPIKE_SARS2]] attaches the virion to the cell membrane by interacting with host receptor, initiating the infection (By similarity). Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein (PubMed:32142651, PubMed:32075877, PubMed:32155444). Uses also human TMPRSS2 for priming in human lung cells which is an essential step for viral entry (PubMed:32142651). Proteolysis by cathepsin CTSL may unmask the fusion peptide of S2 and activate membranes fusion within endosomes.[HAMAP-Rule:MF_04099]<ref>PMID:32075877</ref> <ref>PMID:32142651</ref> <ref>PMID:32155444</ref> mediates fusion of the virion and cellular membranes by acting as a class I viral fusion protein. Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and target cell membrane fusion, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes.[HAMAP-Rule:MF_04099] Acts as a viral fusion peptide which is unmasked following S2 cleavage occurring upon virus endocytosis.[HAMAP-Rule:MF_04099] | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Vaccine efforts to combat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for the current coronavirus disease 2019 (COVID-19) pandemic, are focused on SARS-CoV-2 spike glycoprotein, the primary target for neutralizing antibodies. We performed cryo-election microscopy and site-specific glycan analysis of one of the leading subunit vaccine candidates from Novavax, which is based on a full-length spike protein formulated in polysorbate 80 detergent. Our studies reveal a stable prefusion conformation of the spike immunogen with slight differences in the S1 subunit compared with published spike ectodomain structures. We also observed interactions between the spike trimers, allowing formation of higher-order spike complexes. This study confirms the structural integrity of the full-length spike protein immunogen and provides a basis for interpreting immune responses to this multivalent nanoparticle immunogen. | ||
| + | |||
| + | Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate.,Bangaru S, Ozorowski G, Turner HL, Antanasijevic A, Huang D, Wang X, Torres JL, Diedrich JK, Tian JH, Portnoff AD, Patel N, Massare MJ, Yates JR 3rd, Nemazee D, Paulson JC, Glenn G, Smith G, Ward AB Science. 2020 Nov 27;370(6520):1089-1094. doi: 10.1126/science.abe1502. Epub 2020, Oct 20. PMID:33082295<ref>PMID:33082295</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 7jji" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| + | [[Category: 2019-ncov]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| - | [[Category: Antanasijevic A]] | + | [[Category: Antanasijevic, A]] |
| - | [[Category: Bangaru S]] | + | [[Category: Bangaru, S]] |
| - | [[Category: Ozorowski G]] | + | [[Category: Ozorowski, G]] |
| - | [[Category: Turner | + | [[Category: Turner, H L]] |
| - | [[Category: Ward | + | [[Category: Ward, A B]] |
| + | [[Category: Glycoprotein]] | ||
| + | [[Category: Immunogen]] | ||
| + | [[Category: Sars-cov-2]] | ||
| + | [[Category: Vaccine]] | ||
| + | [[Category: Viral protein]] | ||
Current revision
Structure of SARS-CoV-2 3Q-2P full-length prefusion spike trimer (C3 symmetry)
| |||||||||||
